Background: Bone ingrowth into a cementless prosthesis can be
achieved by both porous and hydroxyapatite coatings. The purpose of this study
was to compare the performance of a hydroxyapatite-coated proximal sleeve and
a porous bead-coated sleeve in patients managed with a modular revision hip
system.
Methods: Between August 1992 and December 1996, fifty-three
consecutive femoral revisions performed with an S-ROM stem in fifty-two
patients were prospectively randomized at the time of surgery to either a
hydroxyapatite-coated or a porous-coated sleeve. All patients were evaluated
clinically and radiographically at three months, six months, and yearly for a
minimum of two years (average, four years; range, two to 7.5 years). Femoral
defects were classified according to the criteria of Paprosky et al. Six
patients died and four patients were lost to follow-up, leaving forty-two
patients (forty-three hips) as the final study group.
Results: For the entire group, two femoral stems, one of which had
been implanted in a hip with a Paprosky type-II femoral defect and the other
in a hip with a Paprosky type-IIIB femoral defect, required a repeat revision,
one for pain and the other for aseptic loosening. Radiographic evidence of
bone ingrowth was observed in 96% (twenty-six) of the twenty-seven femora with
type-I or II defects and in 81% (thirteen) of the sixteen femora with type-III
defects. Femoral component survival, with use of revision as the end point,
was 95% at four years for the entire group. The Harris hip scores were not
significantly different when stratified by implant type, but were
significantly different when stratified by bone loss (p < 0.05). In the
femora with type-I or II defects, no difference was detected between those
treated with a hydroxyapatite-coated implant and those that received a
porous-coated implant with respect to bone ingrowth. However, in femora with
type-III defects, the likelihood of the development of bone ingrowth was 2.6
(95% confidence interval, 1.3 to 5.17) times greater in hips that received a
hydroxyapatite-coated implant (all eight developed ingrowth) than in hips that
had a porous-coated implant (five of eight developed ingrowth) (p = 0.05).
Conclusions: Bone fixation was achieved more often with
hydroxyapatite-coated sleeves in femora with Paprosky type-III defects, but no
significant difference was noted in outcomes between the two implant types
when used in bone with type-I or type-II femoral defects. Overall, the S-ROM
modular hip stem performed better in femora with type-I or II bone defects
than in femora with type-III defects.
Level of Evidence: Prognostic study, Level II-1
(retrospective study). See Instructions to Authors for a complete description
of levels of evidence.